|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Monitoring T790M with plasma DNA using MBP-QP reflects the clinical course of lung cancer patients treated with EGFR-TKI.
|
26577492 |
2016 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Loss of EPHA2 reduced the viability of erlotinib-resistant tumor cells harboring EGFR(T790M) mutations in vitro and inhibited tumor growth and progression in an inducible EGFR(L858R+T790M)-mutant lung cancer model in vivo.
|
26744526 |
2016 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
First-generation EGFR TKI exposure did not influence the prevalence of T790M in lung cancer acquired resistance to afatinib.
|
26862733 |
2016 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
This review summarizes information about and current treatment strategies for patients with EGFR-mutant lung cancer whose disease progresses on their initial EGFR inhibitor, including those with T790M and other types of acquired resistance.
|
27196961 |
2016 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The impact of intermittent versus continuous exposure to EGFR tyrosine kinase inhibitor on selection of EGFR T790M-mutant drug-resistant clones in a lung cancer cell line carrying activating EGFR mutation.
|
27270313 |
2016 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Moreover, size-selecting for shorter cell-free DNA fragment lengths substantially increased the EGFR T790M mutant allele frequency in human lung cancer.
|
27428049 |
2016 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Discovery of (R,E)-N-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T790M) EGFR Mutants for the Treatment of EGFR Mutant Non-Small-Cell Lung Cancers.
|
27433829 |
2016 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Phase II Study of the EGFR-TKI Rechallenge With Afatinib in Patients With Advanced NSCLC Harboring Sensitive EGFR Mutation Without T790M: Okayama Lung Cancer Study Group Trial OLCSG 1403.
|
27506489 |
2017 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
AC0010, an Irreversible EGFR Inhibitor Selectively Targeting Mutated EGFR and Overcoming T790M-Induced Resistance in Animal Models and Lung Cancer Patients.
|
27573423 |
2016 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Association of EGFR Exon 19 Deletion and EGFR-TKI Treatment Duration with Frequency of T790M Mutation in EGFR-Mutant Lung Cancer Patients.
|
27811988 |
2016 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Staurosporine scaffold-based rational discovery of the wild-type sparing reversible inhibitors of EGFR T790M gatekeeper mutant in lung cancer with analog-sensitive kinase technology.
|
27891677 |
2017 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.
|
27959700 |
2017 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Moreover, this combination could induce apoptosis even when tumor cells acquired <i>EGFR</i>-T790M mutations.<b>Conclusions:</b> These findings indicate the importance of developing HDAC3-selective inhibitors, and their combined use with osimertinib, for treating <i>EGFR</i>-mutated lung cancers carrying the <i>BIM</i> deletion polymorphism.<i></i>.
|
27986747 |
2017 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Superior Efficacy and Selectivity of Novel Small-Molecule Kinase Inhibitors of T790M-Mutant EGFR in Preclinical Models of Lung Cancer.
|
28082405 |
2017 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
As this clinical entity is underrepresented in clinical trials, the practicability of plasma EGFR testing and the optimal dose-response relationship of osimertinib in T790M-positive lung cancer complicated with LM deserves further exploration.
|
28296233 |
2017 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Different resistance mechanisms, especially, T790M secondary acquired point mutation and in some cases amplification of cMET, have been a major setback for the lung cancer therapies.
|
28362115 |
2017 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have changed the treatment strategy for EGFR-mutant lung cancers; however, resistance usually occurs due to a secondary mutation, T790M, in EGFR.
|
28388009 |
2017 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Specifically, these agents can overcome the effects of the T790M mutation, which mediates resistance to first- and second-generation EGFR TKI, and recent clinical trials have documented their efficacy in patients with <i>EGFR</i>-mutant lung cancer.
|
28416483 |
2017 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In this study, we introduced the EGFR T790M mutation into the PC9 human lung cancer cell line-which has a deletion in exon 19 of the EGFR gene-by clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated (Cas)9-mediated genome editing.
|
28422737 |
2017 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Lung cancer harboring epidermal growth factor receptor (EGFR) mutations and treated with EGFR tyrosine kinase inhibitors (TKIs) all eventually develop acquired resistance to the treatment, with half of the patients developing EGFR T790M resistance mutations.
|
28620690 |
2017 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Nowadays, 3rd generation EGFR TKI is widely used for T790M positive 1st and 2nd EGFR-TKI resistant lung cancer patients.
|
28684311 |
2017 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Furthermore, we analyzed 55 cfDNA preparations from patients with lung cancer to compare reliability and sensitivity of the three methods under routine conditions and achieved 96.0% concordance of p.T790M results.
|
28723342 |
2017 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Amplification-refractory mutation system PCR has been used for the analysis of ctDNA to detect resistance-causing mutations in the epidermal growth factor receptor gene (eg, EGFR T790M) in lung cancer patients.
|
28732213 |
2017 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Large Cell Neuroendocrine Carcinoma Transformation and EGFR-T790M Mutation as Coexisting Mechanisms of Acquired Resistance to EGFR-TKIs in Lung Cancer.
|
28778263 |
2017 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The present study established lung cancer cell lines that were resistant to gefitinib or erlotinib, and these cell lines were verified to contain the <i>EGFR</i> T790M mutation.
|
28781659 |
2017 |